As JAK3 mutants are dependent on JAK1 signaling for their cellular transformation, it is possible to use both JAK1/JAK2 and JAK3‐selective inhibitors in JAK3 mutation–positive leukemia [11]. This evidence concerns the gene JAK2 and leukemia.